[go: up one dir, main page]

PE20091888A1 - Inhibidores de catepsina c - Google Patents

Inhibidores de catepsina c

Info

Publication number
PE20091888A1
PE20091888A1 PE2009000536A PE2009000536A PE20091888A1 PE 20091888 A1 PE20091888 A1 PE 20091888A1 PE 2009000536 A PE2009000536 A PE 2009000536A PE 2009000536 A PE2009000536 A PE 2009000536A PE 20091888 A1 PE20091888 A1 PE 20091888A1
Authority
PE
Peru
Prior art keywords
alkyl
halo
cyane
pyrrolidinyl
catepsin
Prior art date
Application number
PE2009000536A
Other languages
English (en)
Inventor
Guoliang Ling
Dramane Ibrahim Laine
Brent W Mccleland
Michael R Palovich
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20091888A1 publication Critical patent/PE20091888A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I), DONDE Rx ES ALQUILO (C1-C6), ARILO, ARIL-ALQUILO (C1-C6) SUSTITUIDO O NO POR HALO, ALQUILO (C1-C6), HALO-ALQUILO (C1-C6), ENTRE OTROS; n ES 1-5; R1 ES HALO, CN, ALQUILO (C1-C10) SUSTITUIDO O NO POR HALO ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-BROMO-N-[(3R)-1-CIANO-3-PIRROLIDINIL]-N-METILBENCENOSULFONAMIDA; N-[(3R)-1-CIANO-3-PIRROLIDINIL]-N-METIL-2,5-BIS(METILOXI)BENCENOSULFONAMIDA; 2,5-DICLORO-N-[(3R)-1-CIANO-3-PIRROLIDINIL]-N-METILBENCENOSULFONAMIDA, ENTRE OTROS. TAMIBEN SE REFIERE A UN METODO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE CATEPSINA C, SIENDO UTILES EN EL TRATAMIENTO DE ENFEMEDAD OBSTRUCTIVA PULMONAR Y SIMILARES
PE2009000536A 2008-04-18 2009-04-16 Inhibidores de catepsina c PE20091888A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4604708P 2008-04-18 2008-04-18

Publications (1)

Publication Number Publication Date
PE20091888A1 true PE20091888A1 (es) 2010-01-17

Family

ID=41152339

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000536A PE20091888A1 (es) 2008-04-18 2009-04-16 Inhibidores de catepsina c

Country Status (7)

Country Link
US (1) US20090264498A1 (es)
AR (1) AR071369A1 (es)
CL (1) CL2009000914A1 (es)
PE (1) PE20091888A1 (es)
TW (1) TW201002318A (es)
UY (1) UY31771A1 (es)
WO (1) WO2009129365A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
WO2013052700A1 (en) * 2011-10-04 2013-04-11 The Brigham And Women's Hospital, Inc. Novel sulfonamides
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
EP3642196B1 (en) 2017-06-20 2022-08-17 Mission Therapeutics Limited Substituted cyanopyrrolidines with activity as dub inhibitors
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
EP4132925A1 (en) 2020-04-08 2023-02-15 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
US20230219939A1 (en) 2020-05-28 2023-07-13 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
US20230303547A1 (en) 2020-06-04 2023-09-28 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
MX2022015608A (es) 2020-06-08 2023-03-03 Mission Therapeutics Ltd Hexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilos con actividad como inhibidores de la peptidasa especifica de ubiquitina 30 (usp30).
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
EP4441044A1 (en) 2021-12-01 2024-10-09 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396257A1 (en) * 2000-01-06 2001-07-12 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Novel compounds and compositions as protease inhibitors
CA2404630A1 (en) * 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors

Also Published As

Publication number Publication date
AR071369A1 (es) 2010-06-16
UY31771A1 (es) 2009-09-30
TW201002318A (en) 2010-01-16
WO2009129365A1 (en) 2009-10-22
CL2009000914A1 (es) 2010-04-16
US20090264498A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
PE20091888A1 (es) Inhibidores de catepsina c
PE20091843A1 (es) Inhibidores de catepsina c
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
PE20141322A1 (es) Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina
JO3142B1 (ar) طريقة تحضير 5-ثنائي فينيل -4-أمينو-2-ميثيل بينتانويك أسيد
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
PH12014500947B1 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
EA201071019A1 (ru) Кристаллические формы производных фениламинопиримидина
EA200900066A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UA109774C2 (uk) Кристалічні форми саксагліптину та процес його одержання (варіанти)
PE20140966A1 (es) Quinazolincarboxamida azetidinas
PE20091828A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2
EA201101308A1 (ru) Применение ралфинамида для лечения биполярного расстройства
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
MX2013008696A (es) Composicion saborizante que comprende mentol y mentano-carboxamidas.
TW200635585A (en) Monocyclic substituted methanones
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
AR066972A1 (es) Derivados azapeptidicos
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
FD Application declared void or lapsed